McIlrath & Eck’s Adamas Pharmaceuticals ADMS Stock Holding History

McIlrath & Eck’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,800	Closed	-$46K	–	588
2018 Q2	$46K	Buy	+1,800	New	+$49.8K	0.03%	125

Other funds holding ADMS

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BWCA

Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

McIlrath & Eck's ADMS Position: Q3 2018 in Review

McIlrath & Eck sold out of Adamas Pharmaceuticals (ADMS) in Q3 2018, closing a stake of 1,800 shares — an estimated $46K sold.

McIlrath & Eck first reported a position in ADMS in Q2 2018 and held it in 1 quarter. The position peaked at $46K in Q2 2018. 125 funds tracked by Wall St. Rank hold ADMS as of Q3 2018.

McIlrath & Eck reported no remaining Adamas Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
McIlrath & Eck sold 1,800 Adamas Pharmaceuticals shares in Q3 2018, an estimated $46K.
McIlrath & Eck first reported a position in Adamas Pharmaceuticals in Q2 2018 and held it in 1 quarter.
McIlrath & Eck's Adamas Pharmaceuticals position peaked at $46K in Q2 2018.
125 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2018.

Based on McIlrath & Eck's 13F filing for Q3 2018, filed 13 Nov 2018.